Na Song, Hao Xiong, Ri Xu, Wen-Geng Cheng, Shan He, Shaoyang Deng, Benshan Zhang, Dao Wang
{"title":"年龄增强MAGIC算法预测儿童aGVHD的死亡率:一项多中心研究","authors":"Na Song, Hao Xiong, Ri Xu, Wen-Geng Cheng, Shan He, Shaoyang Deng, Benshan Zhang, Dao Wang","doi":"10.3389/fimmu.2025.1660861","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Acute graft-versus-host disease (aGVHD) is a major contributor to non-relapse mortality (NRM) in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the MAGIC algorithm has been validated in adults, its predictive value in children remains insufficiently explored.</p><p><strong>Methods: </strong>We conducted a prospective multicenter cohort study including 105 Chinese pediatric allo-HSCT recipients diagnosed with aGVHD between May 2019 and August 2023. Endpoints were 6-month NRM, overall survival (OS), and Day-28 treatment response. Multivariable analyses incorporated clinical variables together with the Panel 2 score, hereafter referred to as Panel 2,using Cox regression for NRM/OS and logistic regression for treatment response.</p><p><strong>Results: </strong>Age ≥12 years (hazard ratio 4.36, 95% CI 1.62-11.75; P=0.003) and a high Panel 2 score (HR 3.09, 95% CI 1.08-8.82; P=0.035) were independent predictors of 6-month NRM and OS. The high-risk (HR) group, defined by the combination of age ≥12 years and a high Panel 2 score, had markedly higher NRM than the low-risk (LR) group (71% vs 12.2%; HR 5.00, 95% CI 1.75-9.56; P=0.001) and significantly worse OS (P<0.001). Panel 2 was also predictive of Day-28 treatment response, with lower CR/PR rates in the high versus low group (62% vs 92%; P<0.001).</p><p><strong>Discussion: </strong>The Panel 2 score effectively predicted NRM, OS, and treatment response in pediatric aGVHD. Incorporating age ≥12 years further enhanced risk stratification, enabling clear separation between HR and LR groups. These findings support the potential clinical utility of this combined model and warrant validation in larger, international pediatric cohorts.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1660861"},"PeriodicalIF":5.9000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463633/pdf/","citationCount":"0","resultStr":"{\"title\":\"Age-enhanced MAGIC algorithm predicts mortality in pediatric aGVHD: a multicenter study.\",\"authors\":\"Na Song, Hao Xiong, Ri Xu, Wen-Geng Cheng, Shan He, Shaoyang Deng, Benshan Zhang, Dao Wang\",\"doi\":\"10.3389/fimmu.2025.1660861\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Acute graft-versus-host disease (aGVHD) is a major contributor to non-relapse mortality (NRM) in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the MAGIC algorithm has been validated in adults, its predictive value in children remains insufficiently explored.</p><p><strong>Methods: </strong>We conducted a prospective multicenter cohort study including 105 Chinese pediatric allo-HSCT recipients diagnosed with aGVHD between May 2019 and August 2023. Endpoints were 6-month NRM, overall survival (OS), and Day-28 treatment response. Multivariable analyses incorporated clinical variables together with the Panel 2 score, hereafter referred to as Panel 2,using Cox regression for NRM/OS and logistic regression for treatment response.</p><p><strong>Results: </strong>Age ≥12 years (hazard ratio 4.36, 95% CI 1.62-11.75; P=0.003) and a high Panel 2 score (HR 3.09, 95% CI 1.08-8.82; P=0.035) were independent predictors of 6-month NRM and OS. The high-risk (HR) group, defined by the combination of age ≥12 years and a high Panel 2 score, had markedly higher NRM than the low-risk (LR) group (71% vs 12.2%; HR 5.00, 95% CI 1.75-9.56; P=0.001) and significantly worse OS (P<0.001). Panel 2 was also predictive of Day-28 treatment response, with lower CR/PR rates in the high versus low group (62% vs 92%; P<0.001).</p><p><strong>Discussion: </strong>The Panel 2 score effectively predicted NRM, OS, and treatment response in pediatric aGVHD. Incorporating age ≥12 years further enhanced risk stratification, enabling clear separation between HR and LR groups. These findings support the potential clinical utility of this combined model and warrant validation in larger, international pediatric cohorts.</p>\",\"PeriodicalId\":12622,\"journal\":{\"name\":\"Frontiers in Immunology\",\"volume\":\"16 \",\"pages\":\"1660861\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463633/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fimmu.2025.1660861\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2025.1660861","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
急性移植物抗宿主病(aGVHD)是接受同种异体造血干细胞移植(alloo - hsct)的儿科患者非复发死亡率(NRM)的主要原因。虽然MAGIC算法已在成人中得到验证,但其在儿童中的预测价值仍未得到充分探索。方法:我们进行了一项前瞻性多中心队列研究,包括2019年5月至2023年8月期间诊断为aGVHD的105名中国儿科同种异体造血干细胞移植接受者。终点是6个月的NRM、总生存期(OS)和第28天的治疗反应。多变量分析将临床变量与Panel 2评分(以下简称Panel 2)合并,NRM/OS采用Cox回归,治疗反应采用logistic回归。结果:年龄≥12岁(风险比4.36,95% CI 1.62-11.75; P=0.003)和高Panel 2评分(HR 3.09, 95% CI 1.08-8.82; P=0.035)是6个月NRM和OS的独立预测因子。高风险(HR)组,由年龄≥12岁和高Panel 2评分的组合定义,其NRM明显高于低风险(LR)组(71% vs 12.2%; HR 5.00, 95% CI 1.75-9.56; P=0.001), OS明显较差(讨论:Panel 2评分有效预测儿童aGVHD的NRM、OS和治疗反应。纳入年龄≥12岁进一步加强了风险分层,使HR组和LR组之间能够明确区分。这些发现支持了该联合模型潜在的临床应用,并有必要在更大的国际儿科队列中进行验证。
Age-enhanced MAGIC algorithm predicts mortality in pediatric aGVHD: a multicenter study.
Introduction: Acute graft-versus-host disease (aGVHD) is a major contributor to non-relapse mortality (NRM) in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the MAGIC algorithm has been validated in adults, its predictive value in children remains insufficiently explored.
Methods: We conducted a prospective multicenter cohort study including 105 Chinese pediatric allo-HSCT recipients diagnosed with aGVHD between May 2019 and August 2023. Endpoints were 6-month NRM, overall survival (OS), and Day-28 treatment response. Multivariable analyses incorporated clinical variables together with the Panel 2 score, hereafter referred to as Panel 2,using Cox regression for NRM/OS and logistic regression for treatment response.
Results: Age ≥12 years (hazard ratio 4.36, 95% CI 1.62-11.75; P=0.003) and a high Panel 2 score (HR 3.09, 95% CI 1.08-8.82; P=0.035) were independent predictors of 6-month NRM and OS. The high-risk (HR) group, defined by the combination of age ≥12 years and a high Panel 2 score, had markedly higher NRM than the low-risk (LR) group (71% vs 12.2%; HR 5.00, 95% CI 1.75-9.56; P=0.001) and significantly worse OS (P<0.001). Panel 2 was also predictive of Day-28 treatment response, with lower CR/PR rates in the high versus low group (62% vs 92%; P<0.001).
Discussion: The Panel 2 score effectively predicted NRM, OS, and treatment response in pediatric aGVHD. Incorporating age ≥12 years further enhanced risk stratification, enabling clear separation between HR and LR groups. These findings support the potential clinical utility of this combined model and warrant validation in larger, international pediatric cohorts.
期刊介绍:
Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.